Key Takeaways
- Custom synthesis optimism despite a weak quarter: Revenue fell ~33% QoQ on cold-container logistics and clearance timing, but management calls the opportunity pipeline the best it has ever seen, with multiple phase 2/3 projects and a structural China-exit tailwind.
- Margins held steady at 36% material consumption despite raw material, energy, and logistics cost pressures, a resilience management attributes entirely to its backward integration strategy.
- The China-plus-one shift is now a tangible demand driver: Big pharma is actively looking outside China for custom synthesis, and Divi's sees Europe and the US as capacity-constrained, positioning India, and Divi's, as the primary beneficiary.
- Generic API pricing remains under pressure, but a potential competitor exit could shift a large volume chunk to Divi's, which has already expanded capacity in anticipation.
- What to watch next quarter: Whether the delayed custom synthesis revenue books in Q3, any concrete movement on the Kakinada government clearance, and the pace of qualification for the new MRI contrast media entry.
Custom Synthesis: The Quarter's Miss and the Multi-Year Bet
- The Q2 drop was logistical, not demand-driven: Revenue fell from ~₹1,200 cr to ~₹800 cr QoQ. Management attributes the decline to cold-container availability issues and projects taking longer for certificate-of-analysis clearance, explicitly stating it had nothing to do with regular custom synthesis business loss.
- Quarterly lumpiness is structural: Management repeatedly stressed that custom synthesis should not be viewed quarter-on-quarter because deliveries can lump up based on cold-container availability and customer-driven timing, a volatility investors must accept as inherent to the business.
- The opportunity pipeline is at a peak: Several opportunities received in the last 6 months, mainly in phase 2 and phase 3, with a few customers' NCEs believed to be crossing phase 3 and closer to launch. Management states 2023 and 2024 will be years with a lot of custom synthesis opportunities.
- New project conversion takes 4 to 6 quarters: From qualification through secondary-site formulation qualification to commercial volumes, the timeline is explicit, meaning the current pipeline will begin yielding meaningfully from FY24 onwards.
- The China-exit thesis is playing out: Sourcing from China is becoming very difficult due to confined mobility and geopolitics. Big pharma is looking outside China to Europe, the US, or India. Management argues Europe and the US lack capacity, leaving India with lots of custom synthesis opportunities.
- Fast-track projects are a distinct, high-upside category: Two fast-track phase 3 projects are expected to start yielding in FY24. Management highlighted its unique execution benchmark of delivering hundreds of tons from an NCE gram process, a first in the API industry.
Dr. Murali K. Divi: "Actually, in fact, our Custom Synthesis business looked very optimistic and probably much better than any given time."
Margin Resilience and the Backward Integration Moat
- Material consumption margin held at 36% despite raw material prices, generic API pricing pressure, increasing logistics costs, and energy costs going up 2x to 4x, a stability management calls out as a direct result of backward integration.
- Backward integration was existential, not optional: Management stated that without backward integration, being totally dependent on China for raw materials with prices up 20% to 40% would have made staying in business difficult. The strategy preserved bottomline profitability at 23% to 27%, the pre-fast-track level.
- China dependency reduced by 20% in H1 FY23 versus H1 FY22 through backward integration and supply diversification, with the supply base continuing to be geographically diversified to mitigate geopolitical risks.
- Raw material pressures persist selectively: Base metals like Lithium and Iodine prices have multiplied several times since last year and the trend is expected to persist. Solvents like Toluene continued to increase, and energy costs remained high. Some raw material prices marginally reduced versus the previous quarter.
- New technologies are the next layer of the moat: Divi's is developing flow chemistry, vapor phase chemistry, liquid-liquid, solid-liquid, electrochemistry, and swing technology for solvent reuse to reduce dependency on n-Butyl Lithium, other metals, and solvents, positioning ahead of other companies on energy conservation, green chemistry, and carbon footprint.
- Logistics costs improved sequentially: The global logistics scenario improved with sea and air freight costs reducing during the quarter, though minor disruptions from manpower shortages continued.
Dr. Murali K. Divi: "If we did not take up the backward integration, had we been totally dependent on the supply for the raw material from China with increased prices anywhere from 20% to 40%, it would have troubled us in even staying in business."
Generic API: Pricing Pain, Potential Competitor Exit Gain
- Price pressures continue in generic APIs, with two large competitor pharmas under pressure. Management hears at least one may be leaving certain products, which could shift a large volume chunk to Divi's, which has already expanded and plans to expand further.
- Demand normalization is underway: Post-COVID, regular therapeutic segments are growing with demand returning for anti-infective, anti-arthritic, anti-allergic, and pain killers. Cough and cold medicine demand is increasing as the cold season started, and seasonal variation is normalizing.
- Patent-expiry pipeline is loaded for 2023 to 2025: Processes have been developed for drugs going off-patent in this window. A few DMFs have been filed, the remaining are in process, and customer qualifications are underway. Opportunities should start materializing from FY24 onwards.
- The sartan circle is nearing completion: Divi's is backward-integrated into Ortho Tolyl Benzonitrile (OTB) via photochemistry at hundreds of tons per month, giving a cost advantage across all sartans. With two big-pharma custom synthesis sartans and two generic sartans under qualification, the sartan circle will be complete.
Dr. Murali K. Divi: "The price pressures still are there. You know the two big pharmas who are our competitors, I think for them, it is not very far from, at least one of them going to be what we hear is that they may be leaving. In such a case, probably we will have a large chunk shifting to our side as we already expanded, and we have plans to expand further."
Contrast Media: A New Growth Vector Takes Shape
- Iodine-based contrast media is now commercial: Qualifications are complete for two contrast media products, one with a big pharma and another with the largest contrast media player, and commercial production is ongoing. The iodine-based contrast media market is described as "several billion dollars."
- MRI contrast media entry expands the addressable market: Divi's is entering MRI contrast media with Gadolinium compounds (Gadobutrol, Gadolatrol). Processes have been developed and discussions are underway with leaders in contrast media. The MRI contrast media market is described as "probably much bigger" than the iodine-based market.
- Timeline is long: Sample approvals and qualifications for MRI contrast media "will take more time," a vague but realistic acknowledgment that this is a multi-year build.
- Contrast media APIs for innovators are in qualification: Two contrast media APIs are being produced exclusively for innovators, with all qualification works in process. Multiple DMFs have been filed for contrast media APIs in several regulated markets.
Capacity, Capex, and the Kakinada Waiting Game
- Most new units have commenced: Two blocks remain: one small-volume high-potency compound unit under completion, and one commercial block reflected in ₹500 cr of capital work in progress. The contrast media block has been validated and production has started.
- Kakinada remains in limbo: There has been no movement from the government, and Divi's is still waiting for final state government clearance, though all other statutory and regulatory clearances have been obtained. Management is waiting 6 to 9 months for clearance.
- If approved, Kakinada is a 2 to 3-year journey: Construction completion within 1 year, results starting from the second year, and full qualification, validation, and customer clearance means a fair timeline of 2 to 3 years total.
- Capacity expansion need is acknowledged: Management sees a need to expand in the next 2 to 3 years for fast-track projects (depending on scale: tens or hundreds of tons), new MRI contrast media compounds, and other opportunities.
- Management declined to provide a CAPEX figure for the next 2 years when asked directly, answering instead about backward integration and expansion drivers.
Nutraceuticals and Other Moving Parts
- Nutraceutical utilization is running at ~80% on doubled capacity, with a stable sales run rate of ₹155 to ₹160 cr. The mix depends on campaign combinations (Vitamin D, A, Astaxanthin, Beta-carotene) and customer demand.
- Receivables are sharply down over the past 6 months, in line with reduced custom synthesis sales. Management views this positively as a return to 2021 levels.
- European energy crisis is a watchpoint: Customers at CPHI complained about energy costs for heating and cooling being up 10x, plus logistics cost increases. Management expects this to play out in the coming winter and beyond.
- Revenue declined 13% in constant currency for the quarter on lower sales and a change in product mix.
- Management deflected on whether ₹1,854 cr topline is a base to grow from, stating the company should not be looked at on a quarter-on-quarter basis and did not directly address whether deferrals occurred.
Dr. Murali K. Divi: "I think we have been always saying that we should not be looked at as on quarter-on-quarter basis. It is very difficult, either in the generic or in the Custom Synthesis to look at quarter-on-quarter basis."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| New custom synthesis opportunities begin yielding | Qualifications, secondary-site formulation qualification, then commercial volumes start | 4 to 6 quarters |
| Fast-track phase 3 projects begin yielding | Two fast-track projects expected to start contributing | FY24 |
| Patent-expiry generic API launches | DMFs filed, customer qualifications underway for drugs going off-patent | 2023 to 2025 |
| Kakinada government clearance decision | Waiting for final state government clearance; all other clearances obtained | 6 to 9 months |
| Kakinada construction to commercial output | Construction within 1 year, results from second year, full qualification thereafter | 2 to 3 years from approval |
| Margin pressures persist near-term | Same margin pressures likely in immediate quarters before new opportunities lift growth | 1 to 2 quarters |
| MRI contrast media entry | Sample approvals, then qualifications; processes developed, discussions with leaders underway | "Will take more time" |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Consolidated total revenue | ₹1,935 cr, vs ₹2,007 cr in Q1 FY23 |
| Profit after tax (PAT) | ₹494 cr |
| Profit before tax (PBT) | ₹615 cr |
| EBITDA margin | 36%, vs 38.5% for H1 FY23 |
| Constant currency growth | negative 13%, vs negative 2% for H1 FY23 |
| Forex gain | ₹31 cr, vs ₹87 cr for H1 FY23 |
| Exports as % of revenue | 87% |
| Exports to US and Europe as % of revenue | 68%, vs 71% for H1 FY23 |
| Product mix: generics vs custom synthesis | 57% / 43%, vs 52% / 48% for H1 FY23 |
| Nutraceutical business revenue | ₹163 cr, vs ₹350 cr for H1 FY23 |
| Capacity utilization | 80%–83% |
| Nutraceutical capacity utilization | ~80% |
| Capitalized assets during the quarter | ₹89 cr, vs ₹200 cr for H1 FY23 |
| Capital work in progress | ₹542 cr as of 30 Sep 2022 |
| Cash on books | ₹3,336 cr as of 30 Sep 2022 |
| Receivables | ₹1,840 cr as of 30 Sep 2022 |
| Inventories | ₹2,970 cr as of 30 Sep 2022 |
| Dependency on China for raw materials | reduced by 20% in H1 FY23 vs H1 FY22 |